The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

PharmaScroll announced a new generative AI chatbot called Self-Serve AI. 1 The company describes it as a research and ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder.

As investors react to an ever-changing political climate, Ash Shehata from KPMG explains what factors they're paying ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their ...